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Abstract
Aims To examine the effect of renal denervation (RDN)
on 24-h ambulatory blood pressure (ABP) with a standard
radiofrequency ablation catheter (RF catheter).
Methods Seventy-five patients with resistant hypertension
received bilateral RDN with an RF catheter (6 RF applica-
tions, 1 minute each, 8–12 watts). Seventy patients fulfilled
inclusion criteria with mean systolic ABP ≥140 mmHg
(mean 165/89) despite treatment with ≥3 antihypertensive
drugs (mean 5.9) including a diuretic, and were further
analysed for ABP changes. Follow-up at 1/3/6/12 months
comprised biochemical evaluations and ABP measurement.
At 6/12 months, duplex sonography of the renal arteries
was additionally performed.
Results At 1/3/6/12 months we observed a significant re-
duction in systolic ABP of –15/–17/–18/–15 mmHg (n =
55/53/57/50; non-parametric Friedman test, p < 0.001) and
diastolic ABP of –6/–9/–10/–7 mmHg (p < 0.001). Of the
patients, 70 %/64 % showed a systolic ABP reduction of
≥10 mmHg, and 77 %/70 % of ≥5 mmHg at 6/12-month
follow-up. Two patients (2.7 %) developed renal artery
stenosis (>70 %) with subsequent stenting without com-
plications. Logistic regression analysis with systolic ABP
reduction ≥10 mmHg at 12 months follow-up as criterion
revealed that only the mean baseline systolic ABP was sig-
nificant, OR = 2.174.
Conclusions RDN with a standard RF catheter can be used
safely to reduce mean ABP in resistant hypertension as
shown in long-term follow-up.
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Introduction
Arterial hypertension is a major global health problem that
affects 30–45 % of the general population [1]. Cardiovas-
cular complications are common in hypertensive patients.
Thus, it is mandatory to achieve a fast and adequate blood
pressure (BP) control. The first step in the antihypertensive
treatment should always be lifestyle modification followed
by an appropriate medical therapy [2], including the use
of single-pill combinations and the avoidance of interfering
substances [3]. However, an increasing number of espe-
cially elderly patients do not respond to antihypertensive
therapy in an adequate manner [4]. Resistant hypertension
is diagnosed when BP levels remain above 140/90 mmHg
despite the use of three antihypertensive drugs at opti-
mal dosages, including a diuretic [1]. As a new invasive
treatment for resistant hypertension, the successful use of
catheter-based renal denervation (RDN) was first described
in the two landmark studies HTN-1 and HTN-2 [5, 6]. In
both studies significant reduction of office-based BP fol-
lowing bilateral RDN was demonstrated with an on-going
treatment effect up to three years of follow-up [7, 8]. In
2014 the first blinded randomised controlled RDN trial with
the large number of 535 patients was published. In contrast
to the HTN-1 and HTN-2 trials it did not show differences
in BP lowering between RDN and a sham-control procedure
[9]. This study has raised important issues, especially by
providing evidence for the existence of a placebo effect and
raising suspicion for improvement of medication adherence
among study patients [9]. However, despite the major im-
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pact of this large randomised sham-controlled trial, it had
some important methodological issues. More specifically,
some of the operators were inexperienced in the field of
RDN (with only three or fewer RDN procedures). Further,
the study population comprised 25 % Afro-Americans who
are known to respond better to sham procedures than to
RDN. Finally, the antihypertensive drug treatment of the
patients was not truly stable [10].
To answer the question whether RDN is effective or not
in BP lowering in patients with truly resistant hyperten-
sion, more well-conducted studies with longer follow-up
are needed. For this purpose, in comparison with office-
based BP, the 24-h ambulatory BP (ABP) measurement is
a more objective method to identify resistant hypertensive
patients. In addition, the 24-h ABP is a valuable predictor
of adverse outcome in hypertensive patients [11].
In this paper, we present 1/3/6/12 month follow-up data
of an observational, non-controlled study (before – after sin-
gle group study) by using a standard radiofrequency (RF)
ablation catheter for RDN. In order to treat only truly resis-
tant patients, we consequently measured the 24-h ABP for




Patients were eligible if they had a long history of resis-
tant hypertension (>6 months) with a stable antihyperten-
sive treatment for at least 4 weeks, were aged >18 years,
and were not pregnant. To be included in the analysis,
patients had to show a mean baseline systolic 24-h ABP
≥140 mmHg despite medical treatment with at least three
antihypertensive drugs in adequate dosages, including a
diuretic. Before enrolment, secondary causes of arterial
hypertension, including obstructive sleep apnoea (OSAS),
primary hyperaldosteronism, renal artery stenosis (>50 %
lumen diameter reduction), pheochromocytoma, Cushing’s
syndrome, and aortic isthmus stenosis, had to be excluded.
Efficacy endpoint was the mean change in 24-h ABP. Pa-
tients were classified as responders if the mean systolic
reduction in 24-h ABP was ≥10 mmHg. Safety endpoints
were all adverse events (acute and during follow-up). The
study was performed in concordance with the Declaration
of Helsinki. All patients provided written informed consent
prior to the intervention.
Study procedure
Baseline evaluation of patients comprised clinical history,
review of medication, physical examination, blood chem-
istry (including serum creatinine and proteinuria), and 24-h
ABP measurement. The devices took a reading at least
every 30 minutes during the day and every 45 minutes dur-
ing the night. A minimum of at least 14 successful mea-
surements per day and 7 successful measurements per night
were considered sufficient. Our RDN procedure has previ-
ously been described in detail [12]. In short, renal artery
stenosis was excluded by renal angiogram via femoral ac-
cess using a 5-French (F) Judkins right 4 catheter (JR4).
After this, a 7-F 4-mm tip standard steerable RF ablation
catheter (Marinr®; Medtronic Inc., Minneapolis, MN, USA)
was introduced into the renal artery without using a guid-
ing sheet. RF ablation was performed in both renal arteries,
consecutively. We applied six low-power RF applications
(1 minute each, 8–12 watts) along the length of the renal
arteries, separated both longitudinally and rotationally to
achieve a circumferential lesion. During ablation patients
received intravenous narcotic and sedative drugs (midazo-
lam and fentanyl), and intravenous unfractionated heparin
with an activated clotting time between 250 and 300 sec-
onds. Aspirin (100 mg per day) was given during the fol-
lowing three months.
Follow-up assessment at 1/3/6/12 months consisted
of 24-h ABP measurement, physical examination, blood
chemistry (including serum creatinine and proteinuria) and
adverse events. Duplex sonography of the renal artery was
performed at baseline and at 3 or 6 months and 12 months
of follow-up.
Statistical analysis
Continuous variables are expressed as mean ± standard de-
viation (SD). Categorical data are summarised as frequen-
cies and percentages. Test results are reported as follows:
the test statistic (χ2) value, degrees of freedom (df) and the
significance level. Subsequent single comparisons between
baseline and 1/3/6/12-month follow-up were conducted by
Wilcoxon signed-rank tests, utilising a Bonferroni correc-
tion for repeated testing (for a nominal 0.05 level the actual
significance level was set at p < 0.01). To adjust for po-
tential confounding factors in RDN therapy, a multivariate
logistic regression model was performed. Odds ratios (ORs)
with 95 % confidence intervals (CIs) were calculated as an
estimate of mean systolic 24-h ABP reduction ≥10 mmHg.
The statistical analyses were computed with SPSS© (SPSS
Inc., Chicago, IL, USA) statistical software.
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Tab. 1 Baseline patient characteristics
Parameter Mean ± SD or n
(%)
Male sex 46 (61)
Age (years) 63.7 ± 12
eGFR, (ml/min per 1.73 m2) 69.4 ± 24
Fluoroscopy time 6.4 ± 3.5
Comorbidity
Diabetes mellitus 36 (48)
CAD 18 (24)
Chronic renal insufficiency (creatinine
≥130 µmol/l)
12 (16)
Obstructive sleep apnoea (treated) 14 (19)
Body mass index (kg/m2) 31.1 ± 5.5
Number of antihypertensive drugs 5.9 ± 1.4
Beta-blocker 60 (80)
ACE-I/ARB 72 (96)
Aldosterone antagonists 18 (23)
Diuretics 74 (98)
Calcium-channel blockers 58 (77)
Vasodilatators 19 (25)
Alpha-1 blockers 44 (59)
Centrally acting sympatholytics 50 (68)
CAD coronary artery disease, eGFR estimated glomerular filtration




We performed RDN in 75 patients with resistant hyper-
tension. In one patient the ablation catheter could only
be introduced in the left renal artery. In all other patients
we successfully performed bilateral RDN. Five patients ad-
mitted to our hospital for RDN with a documented home-
and office-based systolic BP of >160 mmHg did not show
a mean systolic 24-h ABP ≥140 mmHg and were there-
fore excluded from our 24-h ABP analysis. Nevertheless,
for safety reasons the follow-up assessment was performed
regularly in these five patients. In our 24-h ABP analysis we
included 70 patients (mean age 64 years; 46 male) with se-
vere drug-resistant hypertension (mean baseline 24-h ABP
165/89 mmHg) despite treatment with at least three anti-
hypertensive drugs (mean 5.9) in optimal doses, including
a diuretic (except one patient with end-stage kidney dis-
ease). All of the patients insisted they were adherent to
the prescribed antihypertensive drug treatment. Baseline
parameters of the patients are shown in Tab. 1.
Fig. 1 Mean systolic and diastolic blood pressure (BP) changes in the
24-h ambulatory blood pressure (ABP) following renal denervation at
1/3/6/12-month follow-up. We found a statistically significant reduc-
tion in BP following renal denervation with RF in systolic 24-h ABP
(χ2 (4) = 26.191, p < 0.001) as well as in diastolic 24-h ABP (χ2 (4) =
20.771, p < 0.001). Post hoc Wilcoxon signed-rank tests (with Bonfer-
roni correction) showed significant BP changes in systolic 24-h ABP
at 1/3/6/12 months (all p-values < 0.0001) and diastolic 24-h ABP at
1/3/6 months (all p-values < 0.001) but not at 12 months (p = 0.013).
(*** p < 0.0001, ** p < 0.001)
24-h ABP changes and predictors of successful BP
reduction following RDN
At 1/3/6/12 months we observed a reduction in mean sys-
tolic 24-h ABP of –15 ± 19/–17 ± 17/–18 ± 18/–15 ±
18 mmHg (n = 55/53/57/50) and a mean diastolic 24-h
ABP of –6 ± 12/–9 ± 12/–10 ± 13/–7 ± 13 mmHg (Fig. 1).
The absolute changes in mean ABP are shown in Table 2.
Overall, there was a statistically significant BP reduction
following RDN in mean systolic 24-h ABP (χ2 (4) = 26.191,
p < 0.001) as well as in mean diastolic 24-h ABP (χ2
(4) = 20.771, p < 0.001). Wilcoxon signed-rank tests (with
Bonferroni correction) showed significant BP changes in
systolic 24-h ABP (all p-values < 0.0001) and diastolic
24-h ABP at 1/3/6 months (all p-values < 0.001) but not at
12 months (p = 0.013). Of the patients, 70 %/64 % showed a
systolic 24-h ABP reduction of ≥10 mmHg, and 77 %/70 %
of ≥5 mmHg at 6/12 months of follow-up. Ten out of
70 patients could reduce and 4 out of 70 had to increase
antihypertensive medication during follow-up. Logistic re-
gression analysis with mean systolic 24-h ABP reduction
≥10 mmHg at 12 months of follow-up as criterion revealed
that only the baseline systolic 24-h ABP was significant
(OR 2.14, 95 % CI 1.13–4.15; p = 0.017) (Fig. 2). Fig. 3
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Fig. 2 Multivariate logistic re-
gression model for responders to
renal denervation. Odds ratios
(ORs) with 95 % confidence in-
tervals (CIs) were calculated as
an estimate of 24-h ambulatory
BP (ABP) reduction >10 mmHg
at 12-month follow-up. Only the
mean systolic 24-h ABP at base-
line was a predictor for respon-
ders of renal denervation therapy
(OR 2.14, 95 % CI, 1.13–4.15;
p = 0.017) whereas age, sex,
body mass index (BMI), num-
ber of antihypertensive drugs at
baseline and creatinine at base-
line did not predict response to
renal denervation
Fig. 3 Distribution of systolic 24-h ambulatory blood pressure at
baseline and at 1/3/6/12-month follow-up
shows the distribution of mean systolic 24-h ABP at base-
line, at 1/3/6/12 months of follow-up.
Non-responders
Ten non-responder patients who did not show systolic
24-h ABP reduction below 150 mmHg, and also did not
show a reduction of systolic 24-h ABP ≥10 mmHg at
≥3 months following RDN (time points ranging between
3–12 months), received second-line RDN and from this
time point on were excluded from our analysis [13]. All
other non-responders were analysed further.
Safety
We did not observe any periprocedural complications. Ten
of our patients missed the 12-month follow-up. All pa-
tients had at least one follow-up with duplex sonography
of the renal artery. Two out of 75 treated patients (2.7 %)
developed renal artery stenosis (>70 % lumen diameter) at
3- or 6-month follow-up. In both patients stenting of the
renal artery stenosis was performed without complications.
However, one of these patients with newly diagnosed renal
artery stenosis following RDN (with otherwise uncontrol-
lable resistant hypertension) had previous stenting of the
renal artery (in-stent stenosis). In all other patients (in-
cluding the five patients who did not fulfil the inclusion
criteria) duplex sonography could exclude significant renal
artery stenosis. One of the patients with diabetic nephropa-
thy developed worsening of renal function due to aggressive
treatment with diuretics. Renal function recovered without
further sequelae after reduction of the diuretics. In all other
patients, we did not observe any renal or vascular compli-
cations during the 12 months of follow-up. The renal func-
tion of the patients remained stable (creatinine at baseline:
103 ± 48 µmol/l versus creatinine at 12-month follow-up:
100 ± 29 µmol/l). One patient died because of pulmonary
embolism 9 months after the procedure (not related to the
procedure).
Discussion
To our knowledge, this is the study with the largest num-
ber of patients in whom RDN was performed with standard
RF ablation catheter with to date the longest follow-up. In
contrast to most of the currently available RDN studies,
we exclusively used 24-h ABP measurement for initial di-
agnosis and during follow-up. Using this strict setting, we
observed excellent results in BP reduction with a high num-
ber of BP responders following the RDN procedure, with
a very low rate of renal and cardiovascular complications.
No periprocedural complications occurred.
Neth Heart J (2016) 24:449–455 453
Tab. 2 Mean systolic and
diastolic BP values at baseline,
1, 3, 6 and 12 months
Systolic ABP ± SD
(mmHg)
Diastolic ABP ± SD
(mmHg)
Patients (n)
Baseline 165 ± 21 89 ± 15 70
1 month 149 ± 15 81 ± 12 55
3 months 145 ± 17 81 ± 13 53
6 months 146 ± 18 79 ± 12 57
12 months 146 ± 16 79 ± 13 50
ABP 24-h ambulatory blood pressure; n number of patients
Recently, the “real-world” data of the Global SYM-
PLICITY Registry, a prospective, open-label, multicentre
registry with 998 patients, were published. In this reg-
istry, a reduction of –11.6 mmHg in systolic office BP
and –6.6 mmHg in systolic 24-h ABP was demonstrated
at 6 months [14]. This BP reduction, although significant,
was smaller than that observed in the HTN-1 and HTN-2
trials [5, 6]. Except that fewer patients were included in our
study, the 24-h ABP reduction observed was higher than de-
scribed in the Global SYMPLICITY Registry [14]. Also the
BP responder rate in our study at 6- and 12-month follow-
up was higher (systolic 24-h ABP reduction >10 mmHg
at 6/12 months: 70 %/64 %; >5 mmHg: 77 %/70 %) in
comparison with the Global SYMPLICITY Registry (sys-
tolic 24-h ABP reduction at 6 months >8 mmHg: 48 %;
>5 mmHg: 68 %) [14]. In 2015, two randomised controlled
RDN trials (DENERHTN and Prague-15 study) were pub-
lished [15, 16]. In the DENERHTN study 101 patients were
randomised to receive either standardised stepped-care an-
tihypertensive treatment alone (baseline mean systolic 24-h
ABP 156 mmHg) or in combination with RDN (baseline
mean systolic 24-h ABP 160 mmHg) [15]. In this study,
the observed reduction in systolic 24-h ABP following RDN
with the Symplicity catheter (–15.8 mmHg at 6-month fol-
low-up) was comparable with our results (–18 mmHg).
However, in the standardised hypertensive treatment group
the 24-h ABP reduction was –9.9 mmHg, amounting to an
additional systolic BP reduction of –5.9 mmHg in the RDN
group [15]. The responder rate in systolic 24-h ABP was
not described in the DENERHTN study [15]. In contrast,
the Prague 15-study with 106 randomised patients found no
significant differences in the 24-h ABP between intensive
pharmacological treatment and the RDN group. However,
after 6 months, the number of antihypertensive drugs and
the serum creatinine level was higher in the pharmacolog-
ical treatment group [16]. Keeping in mind that the base-
line patient characteristics were similar in the afore-men-
tioned studies, some important differences might explain
the better BP response in our and in the DENERHTN study.
First, the mean systolic 24-h ABP was 165 mmHg in our
and 159 mmHg in the DENERHTN study, whereas in the
Global SYMPLICITY Registry the baseline mean systolic
24-h ABP was 151 mmHg [14]. As described previously
and confirmed in our and in the DENERHTN study, the
baseline systolic office BP, or mean baseline systolic 24-h
ABP, are to date the only known independent predictors of
BP response following RDN [15, 17, 18].
Second, 41 % of the operators in the Global Symplic-
ity registry performed fewer than 15 RDN procedures with
the Symplicity catheter. In contrast, in our single-centre
study two experienced electrophysiologists performed all
the procedures (>30 RDN procedures per operator). There-
fore, the operators in our study might be more familiar with
the handling of the RF ablation catheter. However, in the
DENERHTN study with similar BP responses, the number
of RDN procedures per operator was also below 10 cases
[15].
Third, we used a 7-F 4-mm tip standard RF ablation
catheter that might provide a higher contact pressure, higher
tip stability and greater torque control during ablation in
comparison with the first-generation Simplicity catheter.
Animal studies conducted by our group found that the RF
ablation for RDN with a standard RF ablation catheter can
be performed without harmful sequelae. Further, we ob-
served an attenuation of neurofilament expression in the
renal artery as a surrogate marker of effective RDN [19].
The performance of these standard RF ablation catheters is
non-traumatic as shown in our study (no acute complica-
tions in the renal artery), and also during RF ablation of the
coronary venous system and the aortic sinus for ablation
of ventricular arrhythmias [20]. In comparison to the re-
sults of the DENERHTN study and the Global Symplicity
registry, RDN using a 7-F 4-mm tip standard RF ablation
catheter seems to be at least as effective as RDN with the
first-generation Simplicity catheter.
According to our data and to data in the literature, there
is a risk of the development of renal artery stenosis fol-
lowing RDN. We observed two new renal artery stenoses
(2.7 %) in our patient sample, detected by duplex sonogra-
phy of the renal artery. However, in one of these patients
(with otherwise uncontrollable resistant hypertension) the
stenosis was an in-stent-restenosis after renal artery stent-
ing that was performed years ago. In contrast, renal artery
stenoses were reported to range between 0.3–1.9 % in the
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Symplicity HTN-1, -2 and -3 trials [8, 21]. No renal artery
stenosis was reported in the Global SYMPLICITY Registry
and the DENERHTN study. However, one could speculate
that renal artery stenosis might be overlooked in the Global
SYMPLICITY Registry since, as in our study, “there was
no mandatory renal artery imaging follow-up” [14] and, es-
pecially in overweight patients, duplex sonography is con-
sidered an inferior imaging modality to magnetic resonance
angiography or angio-CT. In the EnligHTN 1 study (n = 46)
renal artery stenosis occurred in 4.3 % of the treated patients
[22]. In all these cases this resolved after treatment with
renal artery stenting, without further complications.
The effect of RDN between the office BP and the 24-h
ABP measurements differed across the known RDN stud-
ies, reviewed by Verloop et al. and Bunte [23, 24]. One
reason for this might be that the 24-h ABP was not the
primary study endpoint (HTN-1 and 2) [7, 8] or the re-
quired level for study inclusion was rather low (systolic
24-h ABP >135 mmHg in HTN-3 and Global SYMPLIC-
ITY Registry) [9, 14]. However, the 24-h ABP measure-
ment performed in the patient’s own environment provides
more objective results than the office-based BP [25]. In our
opinion, 24-h ABP measurement with BP values that are
beyond 135/90 mmHg as an inclusion criterion should be
used for further RDN trials since a systolic 24-h ABP of
135 mmHg might be too close to the normal range. The
weaker criterion of office-based BP should only be used as
a sub-criterion.
There are some limitations to our study worth noting.
One general concern raised by the negative results of the
first randomised sham-controlled study (HTN-3) [9] is
whether observation studies can still be deemed useful for
evaluating the efficacy of the percutaneous RDN proce-
dure. As a matter of fact, randomised controlled trials are
the gold standard in testing efficacy of medical interven-
tions [26]. Observational studies can be an alternative,
however, when randomised controlled trials are difficult
to perform [27]. As a practical alternative to doing noth-
ing, well-designed prospective observational studies might
be used to obtain more information on treatment effect
and long-term outcome [28]. The HTN-3 trial had some
methodological deficiencies, mentioned above, and there
is evidence from other randomised controlled trials and
also from many observational studies that RDN is effective
and safe [6, 8, 14, 17, 22]. The sample size in our study
with 70 patients analysed is rather small. As we used 24-h
ABP measurement consequently, it is to date the largest
number and longest follow-up of patients in whom RDN
was performed by using a standard RF catheter. Because
of the observational design of our study, we cannot rule out
that the Hawthorne effect (a phenomenon that individuals
modify their behaviour if they are aware they are being ob-
served) [29] might contribute to the BP reduction observed.
Another problem of observational studies is the regression
to the mean (Extreme outliers on the first measurement tend
to be less extreme and closer to the mean on the second
measurement. It can make natural variation in repeated
data assessments look like a real change.) [30]. However,
all of the patients included in our study had a long history
of resistant hypertension with multiple previous clinical
consultations and examinations, BP measurements, inten-
sive review, and adaption of medication without significant
effects on 24-h ABP. Furthermore, the patients had to be
on a stable antihypertensive treatment for at least 4 weeks
before inclusion in our study.
In conclusion, as shown during long-term follow-up our
results support the hypothesis that RDN with a standard
RF ablation catheter can be used safely to substantially re-
duce mean 24-h ABP in resistant hypertension, with an
acceptable risk for the development of renal artery steno-
sis. Thus, our findings support and extend the results of
previous studies that RDN is effective in BP reduction. In
our study, only the mean systolic 24-h ABP at baseline was
a predictor for responders and should therefore be used as
the inclusion criterion for further RDN studies. However,
for a final judgement of the efficacy of RDN, randomised
trials with long follow-ups are needed.
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